

PIRAMAL HEALTHCARE LIMITED
Piramal Tower, Peninsula Corporate Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai - 400013.

STANDALONE AUDITED FINANCIAL RESULTS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2010

(Rs. in Lakhs)

Particulars	3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for current period ended	Year to date figures for the previous year ended	Previous accounting year ended
	30/09/2010 (Unaudited)	30/09/2009 (Unaudited)	30/09/2010 (Audited)	30/09/2009 (Unaudited)	31/03/2010 (Audited)
Net Sales / Income from Operations	53,749	70,554	110,507	127,088	265,094
Other Operating Income	255	216	533	655	1,527
Net Sales / Income from Operations	54,004	70,770	111,040	127,743	266,621
Expenditure					
(Increase) / Decrease in stock in trade and work-in-progress	13,490	(2,293)	8,398	(3,457)	(2,184)
Consumption of Raw Materials	1,309	18,183	14,021	31,881	61,085
Purchase of Traded Goods	9,139	14,309	25,097	24,513	51,362
Employees Cost	7,557	8,252	16,620	15,412	29,893
R&D Expenses	867	974	1,863	1,911	3,619
Depreciation	2,300	2,306	4,840	4,572	9,222
Foreign Exchange (Gain)/Loss (Net)	1,052	231	660	218	1,061
Other Expenditure (Net)	21,573	16,279	35,905	30,959	62,416
Total Expenditure	57,287	58,241	107,404	106,009	216,474
Profit/ (Loss) from Operations before Interest & Exceptional Items	(3,283)	12,529	3,636	21,734	50,147
Other Income	2,030	389	2,031	392	1,165
Profit/ (Loss) before Interest & Exceptional Items	(1,253)	12,918	5,667	22,126	51,312
Interest Income/(Expense) (Net)	1,356	(720)	1,195	(1,589)	(3,550)
Profit after Interest but before Exceptional Items	103	12,198	6,862	20,537	47,762
Exceptional (Income)/Expenses (Net)	(1,620,990)	36	(1,620,990)	36	36
Profit before Tax	1,621,093	12,162	1,627,852	20,501	47,726
Tax Expense	364,095	740	364,163	1,668	3,404
Net Profit from Ordinary Activities after Tax	1,256,998	11,422	1,263,689	18,833	44,322
Extraordinary Items (net of tax expense)	-	-	-	-	-
Net Profit for the Period	1,256,998	11,422	1,263,689	18,833	44,322
Paid-up Equity Share Capital (Face Value Rs.2/- each)	4,180	4,180	4,180	4,180	4,180
Paid-up Debt Capital					35,000
Reserves (Excluding Revaluation Reserves)					145,883
Debenture Redemption Reserve					6,500
Earnings Per Share (EPS)					
a) Basic and diluted EPS before extraordinary items for the period (Rs.)	601.4	5.5	604.6	9.0	21.2
b) Basic and diluted EPS after extraordinary items for the period (Rs.)	601.4	5.5	604.6	9.0	21.2
Debt Service Coverage Ratio (Refer Footnote No. 1)	-	-	6.8	9.4	10.6
Interest Service Coverage Ratio (Refer Footnote No. 2)	-	-	NA*	16.8	17.0
Public Shareholding					
- Number of shares	100331208	105599880	100331208	105599880	106087962
- Percentage of shareholding	48.00%	50.52%	48.00%	50.52%	50.76%
Promoters and Promoter group Shareholding					
a) Pledged/Encumbered					
- Number of shares	-	8420000	-	8420000	8420000
- Percentage of shares (% to total shareholding of promoters and promoter group)	-	8.14%	-	8.14%	8.18%
- Percentage of shares (% to the total share capital of the company)	-	4.03%	-	4.03%	4.03%
b) Non-encumbered					
- Number of Shares	108681936	94993264	108681936	94993264	94505182
- Percentage of shares (% to total shareholding of promoters and promoter group)	100.00%	91.86%	100.00%	91.86%	91.82%
- Percentage of shares (% to the total share capital of the company)	52.00%	45.45%	52.00%	45.45%	45.21%

Footnotes:

1. Debt Service Coverage Ratio = Earnings before Interest, Depreciation and Tax/ (Interest Expense + Principal Repayment)

Debt = Long Term Debt

Interest Expense = Interest on Long Term Debt

2. Interest Service Coverage Ratio = Earnings before Interest, Depreciation and Tax / Net Interest

* On Account of Net Interest Income Earned in the current period.

Notes on Standalone Results:

1. The standalone results for the quarter and half year ended September 30, 2010 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 22, 2010. The standalone result for the half year ended September 30, 2010 have been subjected to audit and includes results for the quarter ended June 30, 2010 which have been subjected to limited review by the statutory auditors.
2. The only individually reportable business segment is pharmaceutical business.
3. Exceptional items for the half year ended September 30, 2010 consists of :-
 - a. Profit on sale of domestic formulation business of Rs. 16,006.62 crores.
 - b. Profit on sale of investment of shares in Piramal Diagnostic Services Private Limited (PDSPL) of Rs. 266.30 crores.
 - c. Provision for diminution in value of investment in Biosyntech Inc., Canada of Rs. 22.32 crores.
 - d. Closure cost of Vitamin and Fine Chemical Plant, Thane of Rs.40.70 crores.
4. The Company had entered into Business Transfer Agreement (BTA) with Abbott Healthcare Private Limited (Abbott), dated May 21, 2010 for sale of its Domestic formulation business ("Business") to Abbott on slump sale basis for net cash consideration of USD 3.8 Billion of which USD 2.2 Billion is received and balance USD 1.6 Billion is receivable on deferred payment basis equally over the next four years. The transaction has been approved by the Board of Directors in its meeting held on May 21, 2010 and by the shareholders on June 25, 2010. The transaction was concluded on September 07, 2010. The Company recognised a profit of Rs.16,006.62 crores on account of sale of the Business.

The net profit of the Business in respect of the ordinary activities attributable to the discontinued operation is:

(Rs. In crores)

Particulars	For the Quarter Ended September 30, 2010		For the Half Year Ended September 30, 2010	
	2010	2009	2010	2009
Profit After Tax	49.98	153.15	150.72	257.05

The carrying amount of total assets and liabilities pertaining to the Business are as follows:

Particulars	(Rs. In crores)
	As At September 07, 2010
Total Assets	738.69
Total Liabilities	131.52

5. Pursuant to the approval of duly authorized committee of directors on July 13, 2010, the Company has sold its 97.5% holding (3,859,200 Equity shares) of Piramal Diagnostic Services Private Limited to Super Religare Limited (SRL) for consideration of Rs.362.97 crores. The consideration has been discharged by cash of Rs.66.35 crores, Equity Shares of Super Religare Limited of Rs.131.62 crores (5,069,902 Rs.10/- each at a premium of Rs.249.62/-) and 16,500 10% cumulative redeemable debentures of Rs.100,000/- each valuing Rs.165.00 crores for its 97.5% share in PDSPL. In addition SRL has assumed a liability of the Company's outstanding loan of Rs.227.71 crores in PDSPL which has been subsequently paid off. The Company recognised profit of Rs.266.30 crores on account of sale of the investment in the subsidiary.
6. The Company held 7,500,000 equity shares as investment in Biosyntech Inc., Canada which has filed for bankruptcy protection under the Bankruptcy and Insolvency Act, Canada. A provision of Rs.22.32 crores has been made towards permanent diminution in the value of the investment.
7. The Board of Directors has approved to shift its manufacturing operation of Vitamins and Fine Chemicals from its Thane Unit to Digwal & Mahad unit. Consequently it has been decided to shut down Thane plant effective September 30, 2010. The total closure cost of the plant (including VRS) is Rs.40.70 crores for which provision has been made.
8. The Current tax includes capital gain tax on sale of Business and sale of Investment in PDSPL of Rs.3,667.68 crores.
9. The figures for the quarter and half year ended September 30, 2009 and year ended March 31, 2010 have been regrouped, wherever necessary.


10. Statement of Assets and Liabilities:
 Disclosure of Balance Sheet Items as per clause 41(v)(h) of the Listing Agreement as at September 30, 2010.

Particulars	(Rs. in Lakhs)	
	As at	
	6 months ended (30/09/2010)	Corresponding 6 months ended in the previous year (30/09/2009)
	(Audited)	(Unaudited)
SHAREHOLDERS' FUNDS		
(A) Share Capital	4,180	4,180
(B) Reserves & Surplus	1,409,572	133,555
LOAN FUNDS	31,260	99,601
DEFERRED TAX LIABILITY (Net)	7,880	9,934
TOTAL	1,452,892	247,270
FIXED ASSETS	69,537	106,060
INVESTMENTS	525,768	13,198
CURRENT ASSETS, LOANS AND ADVANCES		
Inventories	16,456	29,040
Sundry Debtors	13,370	37,356
Cash and Bank Balances	310,943	2,461
Other Current Assets	2,929	901
Loans and Advances	805,047	100,920
	1,148,745	170,678
LESS : CURRENT LIABILITIES AND PROVISIONS		
Current Liabilities	79,274	40,651
Provisions	211,884	2,015
	291,158	42,666
TOTAL	1,452,892	247,270

11. Status of shareholder complaints received during the quarter ended September 30, 2010:

Complaints as at July 01, 2010	2
Complaints received during the quarter ended September 30, 2010	14
Complaints disposed off during the quarter ended September 30, 2010	13
Complaints pending as on September 30, 2010	3

For PIRAMAL HEALTHCARE LIMITED


 Ajay G. Piramal
 Chairman

October 22, 2010
 Mumbai